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OPEN
REVIEW
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function
alarmins
Damien Bertheloot1 and Eicke Latz1,2,3
Our immune system is based on the close collaboration of the innate and adaptive immune systems for the rapid
detection of any threats to the host. Recognition of pathogen-derived molecules is entrusted to speciﬁc germline-
encoded signaling receptors. The same receptors have now also emerged as efﬁcient detectors of misplaced or
altered self-molecules that signal tissue damage and cell death following, for example, disruption of the blood
supply and subsequent hypoxia. Many types of endogenous molecules have been shown to provoke such sterile
inﬂammatory states when released from dying cells. However, a group of proteins referred to as alarmins have both
intracellular and extracellular functions which have been the subject of intense research. Indeed, alarmins can
either exert beneﬁcial cell housekeeping functions, leading to tissue repair, or provoke deleterious uncontrolled
inﬂammation. This group of proteins includes the high-mobility group box 1 protein (HMGB1), interleukin (IL)-1α,
IL-33 and the Ca2+-binding S100 proteins. These dual-function proteins share conserved regulatory mechanisms,
such as secretory routes, post-translational modiﬁcations and enzymatic processing, that govern their extracellular
functions in time and space. Release of alarmins from mesenchymal cells is a highly relevant mechanism by which
immune cells can be alerted of tissue damage, and alarmins play a key role in the development of acute or chronic
inﬂammatory diseases and in cancer development.
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INTRODUCTION
The immune recognition of an infection and the subsequent
battle against the infecting pathogen is governed by the
concerted efforts of both the innate and the adaptive immune
systems. The ﬁrst sensing of microbial invasion requires
germline-encoded signaling receptors, also known as pattern-
recognition receptors (PRRs), that evolved to acquire sensing
speciﬁcity for foreign signature molecules generally termed
pathogen-associated molecular patterns. This system was ﬁrst
theorized by Charles Janeway1 25 years ago, and has since been
extended to include the more recently recognized ability of the
innate immune system to also sense tissue damage by
recognizing mislocalized or altered endogenous molecules
termed damage-associated molecular patterns (DAMPs).2,3
These molecules found in a foreign environment trigger
sterile inﬂammation and, in the best case, promote tissue repair
and the resolution of the inﬂammation. However, innate
immune responses can also fuel uncontrolled or chronic
inﬂammation. Since the introduction of the DAMP model by
Polly Matzinger,2 many molecules that are released during
proinﬂammatory cell death have been ascribed a DAMP
function. These include heat-shock proteins (HSPs), adenosine
triphosphate (ATP), nucleosomes, mitochondrial components
and several alarmins: dual-function proteins that have distinct
roles inside or outside the cells. The term alarmin describes
protein functions leading to a rapid inﬂammatory response upon
the release of these biologically active molecules. Notably,
alarmins are also found in the nucleus in the resting state and
likely exert biologically meaningful, yet understudied, functions.
For example, failure of interleukin (IL)-33 to translocate to the
nucleus results in a lethal inﬂammatory response, suggesting that
the nuclear localization of, in this case, IL-33 has a protective
function.4 In this review, we summarize recent knowledge on
the most thoroughly studied dual-function proteins, the high-
mobility group box 1 (HMGB1) protein, IL-1α, IL-33 and S100
proteins, with a focus on their extracellular functions.
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HIGH-MOBILITY GROUP BOX 1
HMGB1 is one of the most abundant nonhistone nuclear
proteins and is a member of the HMG protein family that
contributes to chromatin architecture and modulates gene
expression. Once released from stromal or immune cells, and
upon interaction with a large panel of cell surface receptors,
HMGB1 exerts a plethora of cell regulatory functions, from
maturation, proliferation and motility to inﬂammation, survi-
val and cell death (Figure 1).
HMGB1 expression, cellular localization and post-
translational modiﬁcations
In resting cells, HMGB1 is localized in the nucleus, where it
exerts an important function for chromatin structure and gene
expression (Figure 1).5,6 HMGB1 is involved in chromosomal
DNA repair and contributes to nucleosome mobility by
promoting histone sliding along the DNA strand. Conse-
quently, Hmgb1 gene knockout is lethal, further arguing for
the importance of HMGB1. Structurally, HMGB1 is composed
of two DNA-binding HMG-box domains, namely Box A and
Box B, followed by a ﬂexible and negatively charged C-terminal
tail. The C-terminal tail is believed to mediate a change in the
three-dimensional structure of HMGB1 from a collapsed to a
more linear conformation that most likely regulates HMGB1
binding to its ligands.7 Interestingly, post-translational mod-
iﬁcations, such as acetylation, methylation and phosphoryla-
tion, have been shown to govern HMGB1 cellular localization
(Figure 1).8–11 Upon activation, monocytes and macrophages
were found to hyperacetylate HMGB1 at nuclear localization
sites, leading to its cytosolic relocalization. This process was
Figure 1 Role of HMGB1 in inﬂammation. Under resting conditions, HMGB1 is localized in the nucleus, where it plays an important role
in chromatin structure and gene expression. The translocation of HMGB1 to the cytoplasm is regulated by post-translational modiﬁcations
such as acetylation, methylation and phosphorylation (1). Because of the lack of a secretion signal, HMGB1 is actively secreted through a
caspase-1-dependent, noncanonical secretory vesicular pathway (2). HMGB1 can also be passively released from damaged cells either
alone or in complex with RNA, DNA or nucleosomes (3). Interestingly, during apoptotic cell death, ROS production induces the terminal
oxidation of HMGB1 that inhibits its proinﬂammatory function and switches HMGB1 function toward tolerogenicity (4). Once in the
extracellular space, HMGB1 binds to several receptors in either free or complexed form (5). HMGB1 receptors, including RAGE and TLR4,
bind free HMGB1 or HMGB1 in complex with DNA or LPS. Through its interaction with RAGE, the internalization of the HMGB1–DNA
complex increases the activation of TLR9 localized in the endosome. However, HMGB1 complex formation with nucleic acids and
potentially with other molecules can be inhibited by direct interaction with TIM-3. Other receptors, such as TLR2, IL-1R and CXCR4,
recruit HMGB1 in complex with nucleosomes, IL-1β or CXCL12, respectively. Thus, sensing of HMGB1 mediates mechanisms of
inﬂammation, cell migration, proliferation and differentiation (6). Furthermore, acting through the CXCL12/CXR4 axis, HMGB1 enhances
chemotaxis (7). HMGB1, high-mobility group box 1 protein; IL, interleukin; LPS, lipopolysaccharide; RAGE, receptor for advanced glycation
end-products; ROS, reactive oxygen species; TLR, Toll-like receptor.
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recently shown to be mediated by the activation of the
JAK/STAT1 (Janus kinase/signal transducer and activator of
transcription 1) pathway.12 In addition, in monocytes, HMGB1
cytoplasmic localization can be regulated by the phosphoryla-
tion of its nuclear localization signal,11 and this was found to
depend on protein kinase C activity.9 Furthermore, in neu-
trophils, HMGB1 cytosolic translocation seems to depend on
the methylation of Lys42 that decreases HMGB1 binding
afﬁnity to DNA and thus enables its translocation to the
cytosol.8 These studies investigated the role of each modiﬁca-
tion in a rather exclusive manner. It is therefore difﬁcult to
conclude whether these mechanisms regulating HMGB1 cel-
lular localization function in parallel or are differentially
modulated in a cell type- or cell activation-dependent manner.
Because the nuclear localization of HMGB1 is likely to act as a
regulatory mechanism with regard to HMGB1 extracellular
function, a more integrative study of HMGB1 post-
translational modiﬁcation will be necessary to better compre-
hend the regulation of HMGB1 cytosolic translocation before
its release.
Adding to the complexity of HMGB1 activity, the redox state
of HMGB1 is believed to orchestrate its extracellular
function.13 HMGB1 possesses three cysteines at positions 23,
45 and 106. These enable three different oxidation states of
HMGB1 that license three mutually exclusive functions:
alarmin, chemoattraction or tolerance.14–16 In fact, the forma-
tion of a disulﬁde bond between Cys23 and Cys45 was shown
to confer proinﬂammatory properties to HMGB1.14,15 Reduced
HMGB1, with all cysteines in the thiol state, loses its alarmin
function and behaves as a chemoattractant.15 In addition, upon
cellular stress or apoptotic cell death, reactive oxygen species
(ROS) production by mitochondria leads to the terminal
oxidation of HMGB1 (sulfonate cysteines), granting HMGB1
tolerogenic properties that seem to mainly depend on Cys106
(Figure 1).16
Consequently, post-translational modiﬁcations orchestrate
HMGB1 activity from cell localization to extracellular function
and thus act as a crucial functional switch.
HMGB1 release and extracellular functions
HMGB1 can be released either passively by necrotic and
damaged cells or by active mechanisms triggered upon immune
cell activation. Once released in the extracellular space,
HMGB1 mediates inﬂammation, cell migration, proliferation
and differentiation (Figure 1).17–19 In fact, extracellular
HMGB1 was shown to act as a chemoattractant for myeloid
cells,20 smooth muscle cells (SMCs)21 and mesoangioblasts,
thereby promoting muscle tissue repair.22
HMGB1 is considered to be one of the most mobile nuclear
proteins and interacts only very transiently with chromosomal
DNA. This loose nuclear DNA binding enables the leakage of
HMGB1 upon cell damage or necrosis.5,23 In contrast, during
apoptosis, HMGB1 was long believed to be trapped inside the
nucleus, where it binds strongly to hypoacetylated chromatin.23
However, it was since demonstrated that oxidized HMGB1 can
be released from late-stage apoptotic cells, thereby promoting
tolerance in a caspase-1-dependent manner.16,24,25 It was also
proposed that macrophages secrete HMGB1 following the
phagocytosis of apoptotic cells,26 thus further challenging the
idea that apoptosis is a ‘silent’ death.
In addition to the cell death-dependent release of HMGB1,
which likely represents its most important role, immune cells
such as macrophages and monocytes are known to actively
secrete HMGB1 once stimulated by cytokines (interferon-γ
(IFNγ), tumor necrosis factor (TNF) and IL-1) or pathogen-
derived molecules (lipopolysaccharide (LPS)).27–30 Moreover,
macrophages release HMGB1 following the activation of the
NLRP3 or NLRC4 inﬂammasomes.27,28,31 Because HMGB1
lacks a leader sequence that would enable its transfer to the
endoplasmic reticulum (ER) and the Golgi, active secretion of
HMGB1 follows a nonclassical vesicular pathway.32 Indeed,
several proteins, including not only HMGB1 but also IL-1β and
IL-18, have been shown to depend on autophagy for their
active secretion through the unconventional secretory
pathway.33,34 Interestingly, following cell starvation, HMGB1
was proposed to enhance autophagy through its interaction
with Beclin1, and this was dependent on ROS production and
the HMGB1 redox state.35 HMGB1 cytoplasmic translocation
both promoted autophagy and limited the apoptotic pathway.
Thus, HMGB1 cytoplasmic translocation not only enables
release but also can actively promote its own secretion.
Several receptors have been shown to trigger downstream
signaling upon binding to HMGB1 either directly or in
complex with other molecules (Figure 1). In macrophages
and dendritic cells, HMGB1 binds directly to Toll-like receptor
4 (TLR4) and induces the secretion of proinﬂammatory
cytokines.36 Interestingly, binding of HMGB1 to TLR4 depends
on reduced Cys106.14,36 Moreover, the activation of TLR4 by
proinﬂammatory HMGB1 (disulﬁde form) was recently shown
to require myeloid differentiation factor 2 (MD-2).37 Upon
binding to TLR4-MD-2, HMGB1 triggers the MyD88-
dependent activation of nuclear factor (NF)-κB and the
subsequent release of proinﬂammatory cytokines (i.e., TNFα,
IL-1β and IL-6). Intriguingly, HMGB1 can also bind directly to
LPS, thereby strengthening its ability to activate TLR4 through
CD14.38 In contrast, binding of HMGB1 to CD24 and the
further mobilization of Siglec-10 (or mouse Siglec-G) was
shown to antagonize HMGB1-induced TLR4 activation in
dendritic cells.39 In this study, Chen et al.39 found that the
effect of CD24/Siglec-10 was restricted to stimulation with
endogenous proteins (HMGB1, HSP70 and HSP90) and did
not hold upon the activation of cells with pathogen-derived
molecules. Hence, the authors proposed that the CD24/Siglec-
10 pathway is a self-regulatory mechanism, limiting deleterious
immune activation by endogenous damage-signaling
molecules.
Another important cell surface receptor for HMGB1 is the
receptor for advanced glycation end-products (RAGE). In fact,
HMGB1 binding to RAGE was demonstrated shortly after
RAGE discovery40 and has since been characterized in many
settings. First, RAGE proved to mediate the previously
described role of HMGB1 in neurite outgrowth during the
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development of the nervous system.40,41 In dendritic cells,
HMGB1 release and sensing by RAGE was shown to be critical
for homing to the lymph nodes and further cross-activation of
T lymphocytes.42–44 In endothelial cells, HMGB1 was further
shown to promote the expression of RAGE and surface
adhesion proteins (intercellular adhesion molecule 1 (ICAM-1)
and vascular cell adhesion molecule 1 (VCAM-1)) and also to
induce RAGE-dependent cytokine production.45–47
In addition to TLR4 and RAGE, HMGB1 interacts with
several more receptors once in complex with other molecules.
Indeed, extracellular HMGB1 can interact with IL-1β,48
CXCL12,49 and nucleosomes,50 thereby promoting the activa-
tion of IL-1 receptor (IL-1R), CXCR4 and TLR2, respectively.
Furthermore, extracellular HMGB1, like other HMGB pro-
teins, is found in complex with either DNA or RNA, promot-
ing sensing by their putative receptors.51–53 Interestingly, yet
another receptor of HMGB1, TIM-3, expressed at the surface
of tumor-associated dendritic cells, was recently shown to
compete with nucleic acids for binding to HMGB1, thereby
dampening the efﬁcacy of antitumor DNA vaccines or
chemotherapy.54 These studies revealed the importance of
controlling the purity of the recombinant HMGB1 protein
used in experiments. In fact, several publications have argued
that high-purity HMGB1 has a limited proinﬂammatory
activity on its own.48,51,53,55 Yet, the propensity of HMGB1
to co-purify with innate immune stimulants is not the only
characteristic that can inﬂuence its biological function. One has
to take into account that different HMGB1 preparations can
vary in their amount of protein oxidation, thus inﬂuencing the
biological activity of recombinant HMGB1. In addition,
although HMGB1 redox status has now been described as a
major regulatory mechanism of HMGB1 extracellular function,
the role of other known post-translational modiﬁcations of
HMGB1 in the extracellular space remains unknown. Hence, in
the future, it would be beneﬁcial to further analyze the
extracellular functions of HMGB1, paying special attention to
its purity and to the exact nature of its post-translational state.
HMGB1 in sepsis and sterile injury
HMGB1 was shown to mediate several acute effects in the
context of infection or sterile tissue damage following myo-
cardial infarction, stroke, acute lung injury or ischemia–
reperfusion injury often occurring after transplantation and
trauma. During sepsis, HMGB1 acts as a late mediator of
inﬂammation that can be sustained for several days and
correlates with an unfavorable prognosis.29 In fact, upon
infection, the presence of large amounts of pathogen-derived
molecules, such as endotoxin, induces a biphasic secretion of
cytokines:56 (1) the release of conventional proinﬂammatory
cytokines, such as TNFα and IL-1β (peak levels are found
within hours) and (2) the late release of HMGB1 that often
leads to lethality. Interestingly, treatment of animals with anti-
HMGB1 antibodies or the HMGB1-binding antagonist throm-
bomodulin provides protection even when administered several
hours after the peak secretion of the early cytokines.45,57 In
accordance with these ﬁndings, conditional deletion of
HMGB1 in myeloid cells protected mice against LPS-induced
endotoxic shock.58 Furthermore, a recent clinical study in
which septic patients were treated with a combination of
Polymyxin B and thrombomodulin found improved survival of
the treated cohort.59 These data argue that HMGB1 may
represent a pharmacological target for the treatment of septic
shock. However, a study with larger groups and across different
microbes and infection routes will be necessary before large-
scale use in the clinic.
It is worth noting that the treatment of septic animals with
recombinant HMGB1 A box, an antagonist competing with
full-length HMGB1 for receptor binding, was also shown to
provide protection against sepsis.60 In addition, the use of a
monoclonal anti-RAGE antibody after cecal ligation and
puncture (CLP) reduced lethality even when it was adminis-
tered 36 h after CLP.61 This study followed the previous work
by Liliensiek et al.,62 who ﬁrst indicated a role for RAGE in the
development of acute inﬂammation during sepsis. In addition
to RAGE, the effects of HMGB1 in sepsis are believed to be
partly mediated through TLR4.37,38 Further reinforcing this
hypothesis, treatment of CLP-elicited septic mice with a speciﬁc
inhibitor of HMGB1 binding to MD-2 (P5779) decreased
lethality.37 However, as mentioned earlier, binding of HMGB1
to LPS strengthens TLR4 activation and thus could potentially
contribute to HMGB1-induced acute inﬂammation following
bacterial infection.
In contrast to its role during sepsis, in the context of sterile
tissue damage and cell death, HMGB1 mediates early inﬂam-
mation responses that only last hours. Indeed, HMGB1 levels
increase in the circulation following major events such as
stroke, myocardial infarction or hemorrhagic shock. These
conditions induce an ischemia–reperfusion injury in tissues
where HMGB1 is passively released.63–69 In these settings, both
TLR4- and RAGE-dependent inﬂammatory pathways mediate
the early effect of HMGB1 release. Indeed, in the ischemic liver
and kidney, TLR4 was shown to trigger inﬂammation in
response to HMGB1 release.64,65 Furthermore, RAGE
expressed at the surface of microglial cells was found to
mediate part of the deleterious function of extracellular
HMGB1 in the ischemic brain.68 Strikingly, following brain
injury, released HMGB1 was found to signal through RAGE in
the lung, thereby mediating pulmonary dysfunction after lung
transplantation.69,70 In accordance with this ﬁnding, HMGB1
release from gut epithelial cells was recently shown to mediate
lung injury following trauma and hemorrhagic shock.71 These
studies illustrate the ability of HMGB1 to mediate its alarmin
function in a systemic manner across the entire body. Here
again, collaboration between RAGE and TLR4 is responsible
for the deleterious effects of HMGB1 in acute sterile inﬂam-
mation. Hence, direct targeting of HMGB1 with antibodies or
thrombomodulin will probably be the most appropriate treat-
ment strategy for transplanted patients or for those suffering
from a traumatic injury. In fact, anti-HMGB1 antibodies have
already shown some success in animal models of sterile
inﬂammation and could therefore be promising for use in
humans.68,72,73
Dual-function alarmins in the heart of inﬂammation and disease
D Bertheloot and E Latz
46
Cellular & Molecular Immunology
Role of HMGB1 in cancer
HMGB1 was studied for many years for its role in cancer and is
now considered a central modulator of cancer development.74
In fact, HMGB1 expression increases in many types of
cancer,75–79 correlates with tumor invasion and metastasis
and relates to unfavorable prognosis.76,77,80,81 At the onset of
tumorigenesis, rapid cell growth can overwhelm the limited
blood circulation, thereby forming an ischemic environment
that induces local cell necrosis and contributes to HMGB1
release.78 Moreover, during hypoxia, released HMGB1 activates
the NLRP3 inﬂammasome and the subsequent caspase-1-
dependent release of IL-1β and IL-18, fostering the inﬂamma-
tory environment and promoting cell invasion.78 Ultraviolet
irradiation of melanoma cells and the subsequent release of
HMGB1 from damaged keratinocytes was also recently shown
to induce a TLR4-dependent inﬂammatory environment that
proved to be an important step toward perivascular invasion
and metastasis in melanoma.82 Intriguingly, in pancreatic
cancer cell lines, the presence of extracellular HMGB1 and its
binding to RAGE seems necessary for mitochondrial ATP
production and sustained cell growth.79 This study proposed
that upon HMGB1 binding, RAGE translocates to the mito-
chondria, where it interacts with electron transport chain
complexes I and II and thereby positively regulates oxidative
phosphorylation. In addition, in the context of colorectal
cancer, released HMGB1 can act on endothelial cells, promot-
ing cell proliferation and neovascularization.81,83 Indeed,
in vitro extracellular treatment with recombinant HMGB1
promotes endothelial cell migration and the NF-κB-dependent
expression of adhesion and angiogenic proteins. Moreover,
treatment with recombinant HMGB1 leads to TLR4 and RAGE
expression. However, knockdown studies showed that
HMGB1-dependent neovascularization is mainly mediated
through RAGE.81 Further emphasizing the role of the RAGE–
HMGB1 axis in cancer progression, blockade of either HMGB1
or RAGE can reduce malignant mesothelioma and glioma
tumor growth and metastasis.80,84 Interestingly, upon antic-
ancer treatment, the HMGB1 redox state balances the cell fate
between autophagy-mediated cell survival or apoptosis.85,86
Indeed, using pancreatic and colon cancer cell lines (Panc2.03
and HCT116, respectively), Tang et al.85,86 demonstrated that
treatment with cytotoxic anticancer agents could induce both
the autophagy and apoptosis pathways and subsequent
HMGB1 release. In this study, the inhibition of autophagy
decreased HMGB1 release and pushed the balance toward
apoptosis. Reduced extracellular HMGB1 promoted autophagy
and cell survival through a RAGE- and Beclin-1-dependent
pathway. In contrast, oxidized HMGB1 promoted cell death
and increased the efﬁciency of chemotherapeutic drugs. In
accordance with these data, studies using different cancer cell
lines (leukemia, colorectal carcinoma and pancreatic cancer
cells) demonstrated a role for both RAGE and HMGB1 in the
balance between autophagy and apoptosis through the mod-
ulation of p53-dependent apoptosis and the activation of
ATG5-dependent autophagy pathways.87–89 In contrast,
HMGB1 has been implicated in the antitumor immune
response induced by radiation therapy or chemotherapy.90,91
In this case, HMGB1 enables the TLR4-dependent activation of
dendritic cells and promotes antigen cross-presentation to
cytotoxic T cells. However, these experiments did not consider
the HMGB1 redox state. Hence, further analysis of the HMGB1
redox state in this setting would be of interest.
HMGB1 mediates chronic inﬂammation
There are many examples of the central role of HMGB1 in the
development and aggravation of chronic inﬂammation. As a
ﬁrst example, extracellular HMGB1 has been associated with
the development of arthritis, particularly with the inﬂammation
of the synovial space. Indeed, HMGB1 levels are increased in
the serum and synovial ﬂuid of patients with rheumatoid
arthritis (RA).92,93 The use of recombinant HMGB1 demon-
strated that extracellular HMGB1 promotes the macrophage-
and neutrophil-dependent development of arthritis.93,94
HMGB1 is actively secreted by synovial macrophages and
ﬁbroblasts in collagen-induced arthritis and hypoxic
conditions.95 In this system, the effect of HMGB1 was shown
to be partly mediated by TLR2 and TLR4.96 Consequently, the
use of anti-HMGB1 monoclonal antibodies, thrombomodulin
or A box peptide efﬁciently diminished inﬂammation and
arthritis.95,97,98 Similarly, blocking HMGB1 release by nuclear
sequestration using oxaliplatin had protective effects.99 In
accordance with these data, gold sodium thiomalate, a mole-
cule often used to treat RA, was shown to block HMGB1
cytosolic translocation and thereby inhibit its secretion from
macrophage cell lines.100
In addition, HMGB1 has been studied for its role in the
development of systemic lupus erythematosus. Indeed, several
studies have found the level of HMGB1 in the serum and skin
lesions to be increased in patients with lupus, and this
correlated with disease activity.101–105 Extracellular nucleo-
somes in complex with HMGB1 are believed to disrupt self-
tolerance and promote the production of anti-double-stranded
DNA antibodies.50,106 HMGB1 binding to DNA contained in
immune complexes was also shown to enhance RAGE-
dependent DNA intake and TLR9 activation, further increasing
cytokine secretion and inﬂammation in lupus patients.51,53
Finally, in atherosclerotic plaques, SMCs are activated to
secrete HMGB1. Interestingly, HMGB1 expression can be
induced upon treatment with cholesterol, further linking
HMGB1 to atherosclerosis.107,108 Upon sensing the Box B
domain of HMGB1, SMCs proliferate and migrate. However,
SMCs are not the only cell type secreting HMGB1 in
atherosclerotic plaques. In fact, endothelial cells, macrophages,
foam cells and activated platelets are also able to secrete
HMGB1.109 As the NLRP3 inﬂammasome contributes to the
formation of atherosclerotic plaques upon activation with
cholesterol crystals,110 and its activation in macrophages leads
to the active release of HMGB1,27,28 it is likely that the
secretion of HMGB1 by plaque-inﬁltrating macrophages is
NLRP3 dependent and contributes to the inﬂammation
induced by cholesterol crystals present in the plaques. In this
context, in vitro experiments showed that treatment with
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D Bertheloot and E Latz
47
Cellular & Molecular Immunology
extracellular HMGB1 increases the expression of adhesion
molecules (ICAM-1 and VCAM-1) and promotes the secretion
of proinﬂammatory cytokines (i.e., TNFα) and chemokines
(i.e., CXCL8 and CCL2).46,47 In addition, RAGE expressed in
endothelial cells is an important mediator of plaque formation.
In fact, RAGE has long been known to promote the expression
of adhesion proteins such as VCAM-1 in endothelial cells.111
During atherosclerosis, RAGE increases HMGB1 expression
and release,112,113 and in vitro treatment of endothelial cells
(human umbilical vein endothelial cells) with extracellular
HMGB1 induces RAGE-dependent ER stress.114 This implica-
tion of the RAGE–HMGB1 axis in the induction of ER stress
could contribute to the previously mentioned induction of
autophagy by HMGB1 through RAGE.89,115 Furthermore,
during atherosclerosis, the HMGB1–RAGE axis has recently
been implicated in platelet activation.116 Hence, in athero-
sclerotic plaques, HMGB1 sensing by platelets, endothelial cells
and SMCs promotes the migration and adhesion of immune
cells, thereby fostering plaque formation and growth.
For the past two decades, HMGB1 commanded the attention
of many groups because of its central role in signaling infection
and cellular damage. It has become clear that even if HMGB1 is
an important mediator of necessary antimicrobial and tissue
repair mechanisms, it also often acts as powerful deleterious
‘double-agent’ in the development of multifactorial diseases
such as cancer and acute or chronic inﬂammation. Hence, the
development of clinical tools targeting HMGB1 to moderate its
negative effects will be crucial for the efﬁcient treatment of
many patients.
INTERLEUKIN-1a
The IL-1 family of proteins contains 11 members. The best-
studied family members are IL-1α and IL-1β. Both are highly
similar in structure and bind to the same cell membrane
receptor, IL-1R. Interestingly, IL-1 receptor antagonist (IL-1Ra)
is a naturally expressed member of the IL-1 family that is
nonimmune stimulatory and inhibits both IL-1α and IL-β
function by competing for binding to their receptor. Members
of the IL-1 family are expressed as pro-forms (pIL-1) that are
usually matured through enzymatic cleavage. Unlike IL-1β but
similarly to all alarmins described herein, IL-1α is a dual-
function cytokine that presents both nuclear and extracellular
functions. Extracellular IL-1α is now recognized to be an
important player in sterile inﬂammatory diseases and
cancer.117–119
IL-1α expression and intracellular function
IL-1α precursor (pIL-1α) is constitutively expressed in most
resting nonhematopoietic cells, such as epithelial cells lining the
gastrointestinal tract, liver, kidney and skin.120,121 Moreover,
pIL-1α expression can be increased in conditions of stress and
inﬂammation.122 In resting cells, pIL-1α is found in the nucleus,
where it promotes gene expression by acting as a transcription
factor (Figure 2),123 regulating cell growth and differentiation.
This relies on the N-terminal domain containing the nuclear
localization signal,124 which is absent in mature IL-1α.124,125
Interestingly, following cleavage, the N-terminal domain of
IL-1α was shown to independently translocate to the nucleus,
where it interacts with certain members of the RNA splicing
and processing machinery.126 In the nucleus, pIL-1α (but not
mature IL-1α) also interacts with histone acetyltransferases and
thus acts as a transcriptional regulator.123,127 In addition, upon
stimulation with LPS or TNFα, pIL-1α translocates to the
nucleus, where it was shown to promote the expression of
inﬂammatory genes such as IL-6 and IL-8.125,128 In accordance
with these ﬁndings, in systemic sclerosis ﬁbroblasts, pIL-1α
translocation was shown to depend on binding to HS1-
associated protein X-1 (HAX-1) and induce the expression of
IL-6 and pro-collagen (Figure 2).129 Interestingly, HAX-1 was
also found to interact with the cleaved IL-1α N-terminal
domain.130 Together, these studies suggest that the nuclear
function of pIL-1α is predominantly dependent on its N-term-
inal domain. Upon cell activation, pIL-1α cleavage acts as a
regulatory mechanism, keeping IL-1α outside the nucleus and
promoting its secretion. Furthermore, pIL-1α cleavage could
support a distinct transcriptional function for the ‘freed’
nuclear N-terminal peptide. However, this hypothesis remains
to be proven.
IL-1α secretion and extracellular activity
In stimulated cells, IL-1α is processed by the membrane-bound
protease calpain, a calcium-dependent cysteine protease, and
then released into the extracellular space.131–134 Similar to
IL-1β and HMGB1, IL-1α does not contain any secretion signal
and thus relies on the noncanonical vesicular secretion pathway
(Figure 2). As for IL-1β, IL-1α secretion is believed to partially
depend on caspase-1 activity.135,136 In fact, it was recently
demonstrated that IL-1α secretion is antagonized by the
intracellular presence of IL-1R2 which, through binding to
pIL-1α, prevents its processing by calpain and further
secretion.134 Active caspase-1 cleaves IL-1R2, thereby enabling
pIL-1α processing by calpain and the release of mature IL-1α.
However, Gross et al.137 showed that caspase-1 dependency for
IL-1α secretion can differ depending on the stimulus and the
targeted inﬂammasomes and does not seem to require the
protease activity of caspase-1. IL-1α secretion may therefore
rely on redundant parallel pathways. In fact, elevated intracel-
lular Ca2+ triggers IL-1α secretion from bone marrow-derived
cells.132,137,138 An increase in the Ca2+ concentration was
shown to be sufﬁcient for inﬂammasome-independent IL-1α
processing by calpain and its subsequent secretion.137 Interest-
ingly, increased levels of Cu2+ were also shown to promote
IL-1α secretion through an S100A13-dependent secretion
mechanism.139,140 Further differentiating itself from IL-1β
and HMGB1, IL-1α activation and secretion is inhibited by
autophagy. Indeed, in the context of Mycobacterium tuberculosis
infection, ATG5-dependent autophagy was shown to block
both the calpain-dependent activation of IL-1α and its secre-
tion, thereby limiting lung inﬂammation and tissue damage.141
Another regulatory mechanism seems to reside in the close
proximity of IL-1α to the nucleus. Indeed, like HMGB1, cells
undergoing apoptosis retain IL-1α in the chromatin fraction,
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whereas necrotic cells can release pIL-1α, resulting in myeloid
cell chemotaxis and inﬂammation.142 In fact, the IL-1α pro-
form is known to bind to IL-1R1 and to induce inﬂammation.
To date, however, it is not entirely clear which of the two forms
is the most relevant following cell damage. Notably, IL-1α
release by stressed endothelial cells was also proposed to be
mediated by the formation of pIL-1α-containing apoptotic
bodies that possessed chemotactic and proinﬂammatory
properties.143
In addition to calpain- and caspase-1-dependent pIL-1α
processing, other proteases, such as granzyme B, elastase or
chymase, have been proposed to cleave pIL-1α, producing the
mature form of IL-1α and potentiating its proinﬂammatory
activity.144 Interestingly, IL-1α may also be displayed at the cell
surface, where it can activate juxtaposing target cells expressing
its receptor, such as T cells or endothelial cells (Figure 2).145–148
As for IL-1β, once it is released into the extracellular space,
soluble or membrane-bound IL-1α binds to IL-1R1 and further
triggers the recruitment of the accessory receptor IL-1R3 (also
known as IL-1RAcP) for signal transduction. Downstream
signaling is triggered by the recruitment of the MyD88 adaptor
protein to the Toll–interleukin receptor domain of IL-1R3.
As for other MyD88-dependent TLR signaling, MyD88 recruit-
ment activates IRAK4/IRAK1 and subsequent downstream
mitogen-activated protein kinase (MAPK) signaling and NF-
κB activation (Figure 2).149,150 Thus, IL-1α activates neighbor-
ing ﬁbroblasts or epithelial cells, further triggering the release of
chemokines that leads immune cells, preferentially
neutrophils,151 to inﬁltrate and enhance local inﬂammation.
IL-1α in sterile inﬂammation: from acute to chronic disease
As previously mentioned, pIL-1α is constitutively expressed in
most resting cells. It is therefore not surprising for pIL-1α to
play a key role in inﬂammation induced by necrosis or tissue
damage following ischemia. Indeed, liver lysates containing
IL-1α promote neutrophilic migration in matrigel.152
Moreover, in peritonitis, IL-1α is released from necrotic cells
and subsequently activates IL-1R1 present at the surface of
mesothelial cells. This was proposed to be the prime event
inducing neutrophil inﬁltration and peritoneal inﬂammation
rather than the HMGB1 pathway.152,153 This proinﬂammatory
role of IL-1α was recently conﬁrmed in a mouse model of
acute colon inﬂammation (dextran sodium sulfate-induced
colitis), where epithelial IL-1α played a key role in the
establishment of inﬂammation.121 In contrast, IL-1β originat-
ing from myeloid cells promoted healing and tissue repair.
One of the main triggers of cell necrosis is the hypoxia that
follows poor oxygen supply associated with, for example, early-
Figure 2 Proinﬂammatory role of extracellular interleukin (IL)-1α. IL-1α precursor (pIL-1α) is constitutively expressed in most resting
nonhematopoietic cells. In these cells, IL-1α is primarily localized in the nucleus, where it promotes gene expression by acting as a
transcription factor (1). IL-1α nuclear transport depends on its interaction with HS1-associated protein X-1 (HAX-1) (2). In stimulated
cells, pIL-1α is processed by the membrane-bound protease calpain, a calcium-dependent cysteine protease, before active release into the
extracellular space through a noncanonical vesicular pathway (3). Interestingly, HAX-1 was also found to interact with the cleaved IL-1α
N-terminal domain, suggesting its independent nuclear function (2). pIL-1α processing is inhibited by the cytosolic expression of IL-1
receptor-2 (IL-1R2) that binds to pIL-1α and thereby prevents its interaction with calpain and its subsequent secretion (4). However, active
caspase-1 cleaves IL-1R2 and thereby enables pIL-1α processing. pIL-1α can also be passively released from damaged cells and, similar
to mature IL-1α, interacts with IL-1 receptor-1 (IL-1R1) (5). In addition to being released in the extracellular space, IL-1α can be
displayed at the plasma membrane, where it activates IL-1R1-expressing juxtaposing cells (6). Once sensed by IL-1R1, soluble or
membrane-bound IL-1α induces the recruitment of the accessory receptor IL-1R3 and triggers proinﬂammatory signaling pathways (7).
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stage tumor growth or blood vessel clogging. Interestingly,
pIL-1α expression was shown to be increased before epithelial
cell necrosis in a hypoxia-induced factor (HIF)-1a- and
HIF-2a-dependent manner.154 The release of IL-1α promotes
chemokine secretion and neutrophil inﬁltration. Moreover,
extracellular pIL-1α itself can trigger the increased expression
of pIL-1α (and pIL-1β) in surrounding cells, thereby fueling
local inﬂammation.151,155 Following this early IL-1α-dependent
inﬂammation and recruitment of neutrophils, inﬂammasomes
and caspase-1 activation enable the cleavage of pIL-1β,
promoting inﬂammation through the recruitment of
macrophages.151,156 This mechanism is conﬁrmed by the IL-1α
dependency of IL-1β secretion following inﬂammasome
activation.137
During brain ischemia, activated platelets present in the
brain vasculature were shown to release pIL-1α and thereby
stimulate endothelial cells to secrete the chemokine CXCL1
and express the endothelial surface adhesion proteins VCAM-1
and ICAM-1. Hence, upon ischemic injury, pIL-1α fosters
inﬂammation by enabling neutrophils to migrate through the
endothelial barrier.157 Interestingly, platelets are known to be
one of the ﬁrst cell types to reach the brain and to be activated
in response to stroke or in patients with multiple
sclerosis.158–160 Thus, platelet-originating IL-1α would be an
early signal playing a central role in the establishment of
cerebrovascular inﬂammation and subsequently devastating
brain injury.
Notably, similar mechanisms are involved in the ischemic
heart following myocardial infarction. Indeed, IL-1α release
from necrotic myocytes was shown to trigger acute inﬂamma-
tion by activating surrounding myoﬁbroblasts.161
The importance of IL-1α and IL-1β in sterile inﬂammation is
further highlighted by the case of patients born with a
deﬁciency in the IL-1R antagonist, IL-1Ra.162,163 Indeed,
deﬁciency in IL-1Ra triggers IL-1-dependent inﬂammation
and the inﬁltration of neutrophils to the skin, joints and
bones. Systemic treatment with recombinant IL-1Ra (anakinra)
has been an efﬁcient way to decrease inﬂammation and prevent
death.156 However, because anakinra can inhibit both IL-1α
and IL-1β by binding to their common receptor, it is unclear
which is the main cytokine at the root of the sterile
inﬂammation affecting these patients. Nonetheless, anakinra
is currently also used to treat RA as well as neonatal-onset
multisystem inﬂammatory disease.164 Other drugs, such as
monoclonal antibodies (canakinumab) and decoy receptors
(rilonacept), are also used to treat patients presenting with, for
example, juvenile idiopathic arthritis or cryopyrin-associated
autoinﬂammatory syndrome, this time with a clear aim at
blocking IL-1β-derived inﬂammation.156
Yet, some evidence suggests a role for IL-1α in the
development of these chronic inﬂammatory diseases. In fact,
early IL-1α release is recognized as an important step that
initiates inﬂammation, and IL-1α is thus considered a promis-
ing target for the treatment of rheumatologic disease.156,164
Interestingly, RA patients producing IL-1α-speciﬁc autoantibo-
dies in the joint synovial ﬂuid show reduced joint erosion.165
This supports the idea that IL-1α is a major player in the
establishment of long-term inﬂammation. Furthermore, in a
recent clinical trial, Coleman et al.166 used a monoclonal
antibody (MABp1) targeting IL-1α for the treatment of
psoriasis.
The role of IL-1α in cardiovascular diseases is not restricted
to its proinﬂammatory function following myocardial infarc-
tion. Indeed, mounting evidence now suggests an important
role for IL-1α in the development of atherosclerosis.167,168 This
might come as a surprise because IL-1β has long been predicted
to be the most important IL-1 cytokine responsible for vascular
inﬂammation and the development of atherosclerotic plaques.
Indeed, mice lacking either IL-1R or IL-1β or those treated
with IL-1β-blocking antibodies presented decreased plaque
formation.169,170 However, others have since shown that IL-1α
deﬁciency in hematopoietic cells has an even more important
protective effect.171,172 Together, these results therefore indicate
a potential role for both IL-1α and IL-1β in atherosclerosis.
Perhaps, the greater effect of IL-1α in the development of
aortic plaques might be in part attributed to the fact that IL-1α
deﬁciency induces the decreased expression of IL-1β,172 thereby
not only acting on IL-1α-dependent cell signaling but also
acting in parallel on IL-1β function. Nevertheless, another
study recently conﬁrmed the results of Kamari et al.172 and
further showed that IL-1α (but not IL-1β) secretion from LPS-
primed macrophages is induced by unsaturated fatty acids (i.e.,
oleic acid) in an inﬂammasome-independent manner.173. In
this study, unsaturated fatty acids were shown to act on the
mitochondrial respiratory chain and induce its uncoupling,
thereby promoting calcium ﬂuxes and subsequent calpain-
dependent IL-1α release. Moreover, by inducing mitochondrial
uncoupling, oleic acid not only promoted IL-1α secretion but
was also shown to inhibit IL-1β release. Hence, unsaturated
fatty acids accumulating in atherosclerotic plaques would shift
the IL-1 secretion by macrophages from IL-1β to IL-1α.
Strikingly, analysis of IL-1α and IL-1β expression in either
IL-1α/β-deﬁcient macrophages indicated that not only IL-1α
was upstream of IL-1β secretion but also that the reverse was
potentially true. Indeed, IL-1β-deﬁcient but not IL-1R-deﬁcient
macrophages showed markedly decreased IL-1α secretion and
LPS-induced expression. This may indicate the existence of an
IL-1β-dependent intracellular transcriptional control of IL-1α
expression. However, this effect was only found in macro-
phages derived from the Il1btm1Yiw background. Macrophages
derived from the Il1btm1Dch background had no effect on IL-1α
secretion. These ﬁndings reveal the potential misconception
regarding the role of IL-1β in atherosclerosis that might have
been the result of underlying partial IL-1α downregulation.
Caution will therefore be needed in the future when studying
the role of IL-1β in atherosclerosis development.
IL-1α in cancer development
The existence of a link between chronic inﬂammation and the
onset of tumorigenesis has long been postulated and is
supported by many clinical conditions as well as cancer animal
models.174–176 Yet, inﬂammation is also necessary for the
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organism to ﬁght against the tumor.177 In the middle of this
tight equilibrium, the presence of proinﬂammatory signals,
such as the previously mentioned HMGB1, can lead to tumor
growth and invasion either way.74 Interestingly, IL-1R auto-
crine stimulation by IL-1α and downstream MyD88 activation
were shown to be crucial for the establishment of the
inﬂammation involved in RAS-dependent carcinogenesis.178
In these settings, IL-1α and MyD88 (but not IL-1β) activation
trigger the loss of keratinocyte differentiation and promote
invasiveness. Similar results have previously been found in
melanoma patients, where IL-1α induced the MyD88-
dependent activation of the NF-κB and MAPK pathways as
well as an increase in ROS production, thereby promoting
tumor progression.179 Furthermore, in pancreatic ductal ade-
nocarcinoma, tumor-associated IL-1α release, probably
through cell damage, can also induce tumor growth via
immune activation of the surrounding tumor ﬁbroblasts.180
IL-1α is furthermore implicated in tumor vascularization by
promoting the expression of vascular endothelial growth factor
(VEGF) in endothelial cells.181 Interestingly, IL-1α seemed to
have a more dramatic effect in hypoxic conditions, which ﬁts
to the proposed role of IL-1α in the often hypoxic tumor
microenvironment. Following these ﬁrst steps of tumor devel-
opment, IL-1β takes over and is thus believed to be of greater
importance.182 Yet, clinical trials are underway using MABp1
antibody to target IL-1α in the treatment of refractory cancers
with metastasis.183
In contrast to the role of secreted IL-1α, intracellular and
membrane-bound IL-1α activates immune mechanisms that
lead to tumor destruction. Indeed, in a large panel of cancer
cell lines, pIL-1α modulates cell cycle and induces
apoptosis.126,184 In addition, overexpression of membrane-
bound IL-1α at the surface of ﬁbrosarcoma or lymphoma
cell lines induced loss of tumorigenicity. Once injected into
mice, such cells form tumors that rapidly regress or cannot
grow.185–187 Furthermore, after injection into wild-type
(WT) mice, these cells induced the appearance of a long-
term memory against tumor cells that relied on the
inﬁltration of CD8+ T cells, natural killer (NK) cells and
macrophages.
Together, these data show that IL-1α could, in certain
settings, represent a key initiator of proinﬂammatory mechan-
isms that drive chronic inﬂammatory diseases. Drugs in clinical
use, such as anakinra, give hope for the targeting of IL-1α in
these pathologies. However, the complex multifaceted func-
tions of IL-1α, sometimes beneﬁcial and at other times
deleterious, make IL-1α a difﬁcult clinical target.
INTERLEUKIN-33
IL-33 is a member of the IL-1 family that is mainly expressed in
the epithelium lining the surfaces in contact with the environ-
ment. IL-33 has long been considered to exclusively mediate
type-2 immune responses. However, recent ﬁndings extended
its inﬂuence to a broader panel of functions at the junction
between innate and adaptive immune responses, from the
maintenance of homeostasis to the mediation of deleterious
proinﬂammatory reactions.
IL-33 protein expression and post-translational modiﬁcation
Similar to IL-1α, IL-33 is an alarmin mostly expressed in
stromal cells, such as endothelial cells, ﬁbroblasts and the
epithelial cells of tissues in contact with the environment. IL-33
(before known as NF-HEV) localizes to the nucleus thanks to a
signal present at its N-terminal end (Figure 3).188,189 Because of
its nuclear location and its release upon the loss of cell integrity,
IL-33 was proposed to be another dual-function alarmin in line
with HMGB1 and IL-1α.190 However, unlike HMGB1 and
IL-1α, nuclear IL-33 represses gene expression by facilitating
chromatin compaction.191 Furthermore, in addition to repres-
sing gene expression, IL-33 nuclear location was recently
shown to act as a strong regulator of IL-33 extracellular
function.4 Indeed, in chimeric mice expressing a N-terminally
truncated IL-33, the exclusion of IL-33 from the nucleus
induced lethal inﬂammation, suggesting that its nuclear
location acts as a sink, preventing its uncontrolled extracellular
release. This IL-33 nuclear ‘docking’ is even more important
since its release is independent of prior processing either by
caspase-1, caspase-8 (required for IL-1β or IL-18) or calpain
(required for IL-1α).192,193 In fact, processing by capsase-1 or
apoptotic caspases (caspase-3 and -7) occurs inside the
IL-1-like domain, after asparagine 178, and was reported to
inactivate the alarmin function of IL-33.194,195 Inactivation of
IL-33 by caspases led at ﬁrst to the consensus that full-length
IL-33 is the active form (Figure 3). Yet, it was since proposed
that IL-33 is cleaved to a mature and more proinﬂammatory
form.196 In fact, in vitro studies demonstrated the cleavage of
IL-33 by neutrophil elastase and cathepsin G. The resulting
C-terminal cleavage products, containing the entire IL-1-like
domain, had stronger proinﬂammatory activity (Figure 3).
However, it remains unclear whether IL-33 processing is
physiologically important, and deeper study of the nature of
released IL-33 in a pathological environment is required. Once
released, IL-33 binds to a member of the IL-1R family, ST2
(also known as IL-1RL1),197 through which IL-33 can activate
both innate and adaptive immune cells. Indeed, ST2 is
particularly expressed in lymphocytes, such as T helper 2
(Th2) cells and mast cells.198,199
Further amplifying the similarity of IL-33 with other
alarmins, a recent study demonstrated that post-translational
modiﬁcation of IL-33 is an important regulator of IL-33
inﬂammatory function.200 However, unlike HMGB1, the
oxidation of IL-33, occurring rapidly in the extracellular space,
proved to be a crucial downregulator of IL-33 function
(Figure 3). Such a mechanism would limit IL-33 in time and
space, restricting its activity to the local environment. Inter-
estingly, this study also showed that all IL-1 family members
(except IL-1α and IL-36β) are subject to oxidation, thus
revealing a potential common regulatory mechanism.
Dual-function alarmins in the heart of inﬂammation and disease
D Bertheloot and E Latz
51
Cellular & Molecular Immunology
IL-33 downstream signaling
Similar to IL-1/IL-1R1 signaling, upon binding of IL-33, ST2
activation requires the accessory receptor IL-1R3 to
function.198,199 Upon activation, ST2/IL-1R3 trigger signal
transduction through a MyD88-IRAK-dependent pathway,
leading to NF-κB, c-Jun N-terminal kinase (JNK) and MAPK
activation.197 Thus, in mast cells, activation of NF-κB leads to
the production of proinﬂammatory cytokines, such as IL-1β,
IL-6 and TNFα.193,201,202 However, in mast cells or T cells,
production of IL-5, IL-13 and the chemokines CCL5,
CCL17 and CCL24 depends on the activation of MAPK
signaling rather than NF-κB. Importantly, IL-33 activates naive
T cells and promotes their maturation toward a Th2 pheno-
type, leading to the release of Th2-type cytokines and
chemokines.203,204
Interestingly, similar to RAGE, several ST2 splicing variants
exist, producing either full-length, membrane-bound ST2 or a
soluble protein thought to act as decoy receptor (sST2).205 For
example, the use of recombinant soluble ST2 antagonizes the
effect of IL-33 in allergic airway inﬂammation.206 In fact,
soluble ST2 can bind to extracellular IL-33, thereby inhibiting
its interaction with membrane-bound and signaling-competent
ST2 (Figure 3).
IL-33 in infection and sepsis
Depending on the context, IL-33 was found to exert either
deleterious or protective effects upon parasitic or viral infection
by driving Th2-type responses. The role for IL-33 in parasitic
infection was ﬁrst suggested by the ﬁnding that upon infection
of mice with Leishmania major, treatment with ST2-speciﬁc
blocking antibodies ameliorated the disease, decreased parasite
replication and switched the T cells toward a protective Th1
response.207 In a similar manner, following infection with
respiratory syncytial virus, treatment with ST2-blocking anti-
bodies reduced lung inﬂammation and the disease severity in
mice primed for Th2-type but not Th1-type responses.208 In
contrast, in the context of Trichuris muris infection, IL-33
expression was enhanced in resistant mice. After infection with
T. muris, treatment with recombinant IL-33 conferred resis-
tance against the infection and promoted a Th2 response (IL-4,
IL-13 and IL-9) whereas it suppressed Th1- and Th17-type
cytokine expression (IFNγ, TNFα and IL-6).209
In the context of systemic inﬂammation, such as that
occurring during sepsis, IL-33 was found to be beneﬁcial.210
Indeed, in the murine CLP model, extracellular IL-33 inhibited
the expression of G protein-coupled receptor kinase-2 (GRK2)
and thereby blocked the TLR4-dependent downregulation of
Figure 3 Extracellular role of interleukin (IL)-33. IL-33 is present in the nucleus of most stromal cells of tissues in contact with the
environment. In the nucleus, IL-33 represses gene expression by facilitating chromatin compaction. Little is known concerning IL-33
translocation to the cytoplasm (1). IL-33 lacks a secretion signal and, therefore, active release may require packaging in noncanonical
secretory vesicles (2). Processing by caspases inhibits the proinﬂammatory function of IL-33 (3). It is therefore likely that IL-33 is released
in its full-length form either actively or passively following cell damage (4). However, in the extracellular space, cleavage of IL-33 by
neutrophil cathepsin G or elastase promotes its proinﬂammatory activity (5). Both full-length and cleaved IL-33 interact with the ST2
receptor and further recruit the accessory receptor, IL-1 receptor-3 (IL-1R3), to trigger proinﬂammatory signals or T helper 2 (Th2)-type
cell maturation and response (6). Interestingly, IL-33 extracellular function is regulated in time and space by rapidly occurring oxidation
that inhibits its binding to ST2 (7).
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the chemokine receptor CXCR2 in neutrophils. This fostered
neutrophil recruitment and microbial clearance at the local
site of infection. Interestingly, although IL-33 did not affect
the local release of proinﬂammatory cytokines, systemic
IL-33 treatment reduced the concentration of blood and lung
cytokines, thereby limiting the systemic inﬂammation induced
by sepsis.
IL-33 and chronic inﬂammatory diseases
In the lung, epithelial cells are the main source of IL-33.
Indeed, upon inﬂammatory stress, epithelial cells can be
damaged and release IL-33 into the extracellular space. For
example, IL-33 was shown to be deleterious during the
development of asthma. In fact, the levels of IL-33 are higher
in asthma patients than in normal individuals,211,212 and the
same is true in a mouse model of ovalbumin (OVA)-elicited
inﬂammation.213 Interestingly, when treated with blocking
antibodies speciﬁc for ST2 or IL-33 at the time of OVA
stimulation, mice presented diminished eosinophil inﬁltration,
less inﬂammation and reduced airway hyperresponsiveness
(AHR).214,215
The role for IL-33 in the development of exacerbated lung
inﬂammation was recently further characterized in the context
of chronic obstructive pulmonary disease (COPD) and viral
infection-induced development of AHR.216 Cigarette smoke is
considered one of the most important causes of COPD
development. Moreover, in COPD patients, viral infection is
often associated with acute exacerbation and AHR.217–219
Kearley et al showed that cigarette smoke induces the increased
expression of IL-33 in epithelial cells.216 Upon tissue damage
induced by viral infection, this increased supply of IL-33 is
released and exacerbates inﬂammation. Interestingly, the
authors also demonstrated that cigarette smoke induced a shift
in the type of immune response by controlling the expression
of ST2 and IL-1R3. Indeed, cigarette smoke induced a dramatic
decrease in ST2/IL-1R3 expression in Th2 T cells and type 2
innate lymphoid cells, thereby reducing the release of Th2-
related cytokines (i.e., IL-5 and IL-13) by these cells. In parallel,
cigarette smoke induced an increase in ST2/IL-1R3 expression
in macrophages and NK cells that led to an increase in the
secretion of TNFα, IL-12 and IFNγ. This could therefore
explain the exacerbated inﬂammation found in COPD patients.
Like HMGB1 and IL-1α, IL-33 was shown to be involved in
other chronic inﬂammatory settings, such as atherosclerosis
and arthritic joint inﬂammation. Indeed, recombinant IL-33
treatment of high-fat-diet ApoE − /− mice, an animal model
of atherosclerosis, induced increased blood concentrations of
IL-4, IL-5 and IL-13, whereas it decreased the level of IFNγ.220
Hence, in these settings, IL-33 switched the immune response
from a Th1-type to a protective Th2-type response. In a similar
manner, IL-33 and ST2 proved to have protective effects in the
context of obesity.221 In fact, treatment of obese mice (ob/ob)
with IL-33 increased the ST2-dependent levels of Th2 cytokines
in the blood and adipose tissue and improved the metabolic
parameters of these mice.
In opposition with its role in atherosclerosis, IL-33 was
previously found to be deleterious in the context of arthritic
joint inﬂammation.222,223 In fact, a dramatic increase in
the synovial and serum levels of IL-33 was detected in
patients with active RA.224 Moreover, when immunized with
collagen, ST2-deﬁcient mice developed strongly reduced
arthritis when compared with WT mice. Treatment with
recombinant IL-33 increased synovial inﬂammation and the
secretion of proinﬂammatory cytokines by mast cells.222 As
expected, treatment of collagen-immunized mice with ST2-
speciﬁc blocking antibodies reduced the development of
arthritic joint inﬂammation.223
Together, the central position of IL-33 at the junction
between the innate and adaptive immune responses makes it
an important modulator of inﬂammation in a broad array of
both acute and chronic inﬂammatory diseases. However,
similarly to HMGB1 and IL-1α, IL-33 may prove to be a
challenging drug target because of its variable effects in distinct
inﬂammatory contexts.
S100
The S100 family of proteins is composed of 25 members that
exert a large variety of intracellular and/or extracellular
functions. Inside cells, S100 proteins regulate cell prolifera-
tion, differentiation, migration, energy metabolism, Ca2+
homeostasis, inﬂammation and cell death. Once released
into the extracellular space, particular S100 proteins act as
alarmins through their interaction with different receptors,
orchestrating both innate and adaptive immune responses,
cell migration and chemotaxis as well as tissue development
and repair.225–227
S100 protein expression and intracellular functions
S100 proteins are part of the calcium homeostasis machinery
that has a crucial role in maintaining sufﬁcient concentra-
tions of intracellular Ca2+ for cell metabolism yet restricting
excessive storage that could lead to Ca2+ precipitation or
overwhelm the cell metabolism (Figure 4). The expression of
the different S100 proteins is cell dependent and is regulated
by speciﬁc growth factors, cytokines or activation of cell
surface PRRs.225,227 Most S100 proteins are of rather small
size (⩽14 kDa) and are encoded by genes clustered on
chromosome 1q21.228 One interesting exception to this rule
is S100B, the coding gene of which is located on chromo-
some 21q22.3 and is found to be overexpressed in patients
with Down syndrome.229,230 S100B is also unique in the fact
that its expression has been associated with cells of neural
crest origin, and it is now considered one of the best
biomarkers of melanoma.231,232
S100 proteins exert their intracellular functions in the
nucleus or cytoplasm by interacting with other target
molecules, such as enzymes, cytoskeletal proteins, receptors,
transcription factors and nucleic acids.227 These interactions
are often a critical step for Ca2+ binding and are therefore
integral parts of calcium homeostasis. Another critical step
for S100 protein activation is the formation of homo- or
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heterodimers. Binding of ions (Ca2+, Zn2+ or Cu2+) occurs via
interactions with the S100 EF-hand domain, a conserved helix-
loop-helix motif found in all calcium-binding proteins. Each
S100 protein present in the dimer contributes to ion binding as
well as to the interaction with the target molecules.233
In healthy conditions, the functions of S100 proteins are
extremely diverse and not only relate to the management of
calcium storage and shufﬂing but also extend to speciﬁc cell
functions, such as scavenging of ROS and nitric oxide
(i.e., S100A8/A9), cytoskeleton assembly (i.e., S100A1,
S100A4, S100A6, S100A9), membrane protein recruitment
and trafﬁcking (i.e., S100A10, S100A12), transcriptional
regulation and DNA repair (i.e., S100A4, S100A11, S100A14,
S100B), cell differentiation (i.e., S100A6, S100A8-A9, S100B),
release of cytokines and antimicrobial agents (degranulation)
(i.e., S100A8-A9, S100A12, S100A13), muscle cell contractility
(i.e., S100A1), cell growth and migration (i.e., S100A4, S100A8-A9,
S100B, S100P) and apoptosis (i.e., S100A6, S100A9, S100B)
(Figure 4). Because of space constraints, we will not discuss
the physiological roles of S100 proteins in additional
detail. However, others have described the biological
mechanisms involving S100 proteins.225,226,228,234–236
S100 protein secretion, receptor interaction and post-
translational modiﬁcations
S100 proteins have been detected in the extracellular space and
certain body ﬂuids, such as serum, urine, sputum, cerebrosp-
inal ﬂuid and feces, where they are generally associated with a
state of disease.237–240 S100A8/A9, S100A12 and S100B are even
considered biomarkers of speciﬁc diseases, such as cancer,
atherosclerosis and stroke.231,241–245
Like all alarmins previously described, S100 proteins lack a
secretion leader sequence and therefore cannot be secreted
through the classical ER–Golgi secretion pathway. The exact
mechanisms that regulate the release of S100 proteins remain
unclear thus far. Nevertheless, the secretion of S100 proteins
occurs either passively upon cell necrosis or actively following
cell activation (Figure 4). In fact, S100A8/A9 and S100A12 (also
called calgranulins) were found to be released actively upon
myeloid cell activation and subsequent tubulin-dependent
translocation to the plasma membrane.245–248 S100A8/A9 were
also found to be part of neutrophil extracellular traps, a
mesh-like agglomerate composed of proteins and nucleic acids
that are released as antimicrobial weapons by activated
neutrophils.249 Similarly, S100B is released upon brain, lung
or muscle tissue damage.250–253
Figure 4 Role of S100 protein in cell housekeeping and inﬂammation. S100 proteins are ubiquitously expressed in all cells and are
crucial regulators of the calcium homeostasis machinery (1). The intracellular functions of S100 proteins also extend to speciﬁc cell
functions such as transcriptional regulation and DNA repair (2), membrane protein recruitment and trafﬁcking (3) and cytoskeleton
assembly (4). The exact mechanisms that regulate the release of S100 proteins remain unclear thus far. Nevertheless, the secretion of
S100 proteins occurs either passively upon cell damage or actively following cell activation (5). Once released into the extracellular space,
S100 proteins interact with several receptors, most importantly RAGE and TLR4 (6). Upon binding to their receptors, S100 proteins trigger
proinﬂammatory pathways promoting cell migration, proliferation and differentiation (7). S100 protein-induced signaling pathways also lead
to the expression of MMPs and CAMs, thereby promoting chemotaxis and tissue remodeling (8). Certain S100 proteins, such as S100A8/
A9, are extremely sensitive to oxidation (9). Their redox state acts as a molecular switch from proinﬂammatory function to protective
wound-healing and antioxidant function. In return, oxidation-sensitive S100 proteins are believed to act as scavengers of ROS and NO and
thereby prevent oxidative stress. CAM, cell adhesion molecule; MMP, matrix metalloproteinase; NO, nitric oxide; RAGE, receptor for
advanced glycation end-products; ROS, reactive oxygen species; TLR4, Toll-like receptor 4.
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Once released to the extracellular space, S100 proteins trigger
immune cell activation through binding to different cell surface
receptors, thereby mediating different effects depending on the
S100 protein and the target cell. Similar to HMGB1, RAGE is
considered the most important cell surface receptor for S100
proteins (Figure 4). S100A12 was the ﬁrst S100 protein for
which binding to RAGE was characterized,254 and this inter-
action is greatly increased by S100A12 capture of Ca2+ or Zn2+
ions.255,256 RAGE N-glycosylation also appears to play an
important role for the recruitment of several S100 proteins
and is believed to promote receptor clustering.257,258 Like
S100A12, S100B binds to the RAGE V-domain and promotes
RAGE multimerization and subsequent activation, thus pro-
moting cell survival.259 In contrast, S100A6 is one of the rare
RAGE ligands shown to interact with the RAGE C2-domain
and was shown to have more of a proapoptotic effect.227,260
Interestingly, at the surface of myoblasts, S100B was shown to
interact with the basic ﬁbroblast growth factor and its receptor,
ﬁbroblast growth factor receptor 1, leading to the recruitment
and subsequent inactivation of RAGE.250 The S100A8/A9
heterodimer has also been proposed to bind to RAGE,
triggering proinﬂammatory signaling and cell migration.261,262
Yet, the binding is rather weak263 and seems to rely on S100A9
and the presence of Ca2+ or Zn2+ ions. In fact, an extracellular
function of S100A8/A9 has been associated with the activation
of other receptors, and this has been the subject of controversy.
Indeed, the S100A8/A9 heterocomplex was ﬁrst believed not to
bind to TLR4, and it was rather the S100A8 homodimer that
was thought to bind to TLR4.264 More contradictory results
came from another study that concluded that S100A9 bound
better to TLR4-MD2 and that this was enhanced by the capture
of Ca2+ and Zn2+.263 Recent data reinforced the potential role
of S100A8 in the activation of TLR4 in monocytes.265 Treat-
ment of mouse and human monocytes with S100A8 closely
resembled LPS stimulation on the transcript level. TLR4 gene
knockdown or steric inhibition studies demonstrated the
proinﬂammatory effect of S100A8 stimulation to be TLR4
dependent.265 Furthermore, other receptors have been impli-
cated in sensing S100 proteins, and these include G protein-
coupled receptors,266,267 scavenger receptors 268,269 and cell
surface heparan sulfate proteoglycans.270
It is important to note that similar to HMGB1 and IL-33,
some S100 protein functions can be modulated by post-
translational modiﬁcations, such as oxidation.271–273 For exam-
ple, S100A8/A9 are very sensitive to oxidation, and their redox
state acts as a molecular switch from a proinﬂammatory
function (reduced) to a protective wound-healing and anti-
oxidant function (oxidized).271 In contrast, oxidation of S100B
was shown to be necessary for binding to RAGE and the
subsequent increase in the expression of the angiogenic factor
VEGF, an important player in the development of macular
degeneration.273
S100 proteins at the onset of acute inﬂammation
Upon release following cell death and tissue damage, several
S100 proteins are passively released and act as DAMPs,
signaling mainly through RAGE and TLR4, and thus contribute
to the regulation of post-traumatic injury and inﬂammation
following myocardial infarction, stroke or brain trauma.
For example, S100A1 is the most highly expressed S100
protein in cardiomyocytes and was shown to be released upon
cell damage following ischemia–reperfusion injury associated
with myocardial infarction.274,275 Once released, S100A1 acti-
vates the surrounding cardiac ﬁbroblasts through TLR4 and
triggers the MAPK and NF-κB proinﬂammatory pathways.274
However, S100A1 not only promotes proinﬂammatory signals
but also regulates a complex balance between pro- and anti-
inﬂammatory pathways associated with the antiﬁbrotic upre-
gulation of matrix metalloproteinase 9 (MMP9) and the
downregulation of type I collagen and connective tissue growth
factor. Moreover, S100A1-blocking antibodies increased ﬁbro-
sis and infarction size, thus resulting in greater myocardial
dysfunction.274 Hence, S100A1 plays a beneﬁcial role following
heart injury, promoting muscle tissue repair and maintaining
contractility. Similarly, S100A4 release following myocardial
infarction was shown to be protective by promoting SMC
motility, proliferation and differentiation.276 In stark contrast
with S100A1 and S100A4, in a mouse model of angiotensin-
induced cardiac damage, the S100A8/A9 heterodimer was
shown to be released by granulocytes that inﬁltrated the muscle
tissue.277 Once released, S100A8/A9 signaled through RAGE
expressed at the surface of cardiac ﬁbroblasts and thereby
upregulated proinﬂammatory gene expression, inducing the
critical release of cytokines and chemokines. In this model, the
use of blocking S100A9 antibodies reduced the accumulation of
ﬁbroblasts, thus decreasing ﬁbrosis while diminishing local
inﬂammation. These data therefore indicate that the damage-
associated release of S100A8/A9 has the opposite effect of
S100A1 or S100A4 in that it promotes myocardial tissue
inﬂammation and ﬁbrotic scar formation. Similarly, following
myocardial infarction, S100B can be released in high dose from
injured cardiomyocytes and, through RAGE, further promote
cell apoptosis,278 whereas in other contexts, RAGE promotes
autophagy rather than apoptosis.279 S100B also promotes the
RAGE- and NF-κB-dependent secretion of VEGF from cardi-
omyocytes, thereby engaging myoﬁbroblast proliferation and
scar formation.280
Much attention has also been paid to the role of S100B in
the central nervous system (CNS). In the brain environment,
S100B function seems to be regulated by its concentration.
Indeed, at low doses, S100B promotes neuron survival.
However, in higher doses, S100B triggers apoptosis and is
therefore associated with brain damage and neurodegeneration.
In fact, S100B is released after stroke or following surgery and
has been used as a marker to measure the extent of CNS
damage and predict clinical outcome following brain injury.242
S100 proteins and chronic inﬂammation
One example of the involvement of S100 proteins in the
establishment of long-term chronic inﬂammatory disease is
found in atherosclerosis. Indeed, while studying the inﬂuence
of RAGE in the development of atherosclerosis in the
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ApoE− /− mouse model, Harja et al.112 found the critical
contribution of the S100B–RAGE axis in vascular inﬂammation
and endothelial cell dysfunction during atherosclerotic plaque
development. RAGE expression by endothelial cells was found
to increase the expression of adhesion molecules (VCAM-1),
cytokines and chemokines as well as MMP2 in the aortic tissue,
thereby promoting the recruitment of immune cells to the
forming plaque. The in vitro stimulation of primary endothelial
cells with S100B was shown to replicate these ﬁndings and to
trigger the activation of the extracellular signal-regulated
protein kinase-1/2 (ERK1/2) and JNK proinﬂammatory path-
way. In addition to S100B, serum S100A12 levels are increased
in patients with coronary artery disease after plaque rupture.281
Thus, S100A12 is now being considered a biomarker of
coronary artery disease.244 In this circumstance, S100A12
inhibits MMP2, 3 and 9 in atherosclerotic plaques.281 More-
over, the presence of S100A12 promotes remodeling and
calciﬁcation of atherosclerotic plaques in a RAGE-dependent
manner in transgenic ApoE − /− mice expressing human
S100A12 in SMCs.282,283 Plaque calciﬁcation is believed to be
partly mediated by SMCs that, under oxidative conditions,
undergo an S100A12/RAGE-dependent procalciﬁc phenotypic
switch to osteoblast-like cells.283,284 Similarly, S100A8/A9 are
found in abundance in macrophages and foam cells present in
human atherosclerotic plaques, where they were shown to
promote dystrophic calciﬁcation.285,286 However, the
oxidation-sensitive nature of S100A8/A9 present in high
amounts in atherosclerotic plaques might mean that the
complex acts as an oxidant scavenger and thus promotes
wound healing and protects other cell components against
damaging oxidation.271
In correlation with their role in atherosclerosis development,
S100A8/A9 were shown to drive the RAGE-dependent and
hyperglycemia-induced increase of myelopoiesis occurring in
diabetic mice.287 Indeed, in diabetic mice (streptozotocin-
elicited or from an Ins2Akita background), the release of S100A8/
A9 by activated neutrophils induced the RAGE-dependent pro-
liferation of granulocyte and macrophage progenitor cells in the
bone marrow. This increased the total quantity of monocytes and
neutrophils inﬁltrating atherosclerotic lesions and thus impaired
plaque regression. Interestingly, antidiabetic treatment normal-
izing the glycemia of Ldlr− /− atherosclerotic mice was sufﬁcient
to decrease the number of circulating monocytes and neutro-
phils and thereby reduced the atherosclerotic lesions. Most
importantly, an increase in the serum white blood cell count
correlated with a higher S100A8/A9 concentration in patients
with coronary artery disease.287 In accordance with these data,
increased serum levels of S100A8/A9 were found in obese
patients and were linked to the increased expression of the
macrophage marker CD68 in the visceral adipose tissue.288,289
However, S100A8/A9 serum levels were found to be reduced to
normal levels following weight loss. These results, together with
the previously mentioned studies linking S100A8/A9 to ather-
osclerosis development, may partly explain the prevalence of
atherosclerosis associated with obesity and diabetes. In addi-
tion, blood levels of S100A12 have been found to be increased
in diabetic patients and to correlate with a higher risk of
cardiovascular disease development.244
Further implicating S100 proteins in the development of
chronic inﬂammatory diseases, calgranulins (S100A8/A9 and
S100A12) were shown to be involved in the joint inﬂammation
associated with RA.290 S100A8/A9 are highly upregulated in
macrophages and neutrophils from patients with juvenile
rheumatoid arthritis, and S100A8/A9 titers in the serum and
synovial ﬂuid correlates with disease severity.247,291 The
S100A8/A9 and S100A12 synovial ﬂuid protein levels were
found to speciﬁcally correlate with RA and were proposed as
speciﬁc markers to differentiate RA from other forms of
inﬂammatory arthritis.292,293 In this context, S100A8/A9 were
found to originate from monocytes, which release S100A8/A9
upon interaction with activated endothelial cells, thereby
enhancing the inﬂammatory environment.247 Extracellular
stimulation of human monocytes with S100A8/A9 was later
shown to trigger NF-κB activation with subsequent release of
proinﬂammatory cytokines.294 In addition to their monocytic
origin, S100A8/A9 expression was found to be increased in
chondrocytes present in the inﬂamed joints of IL-1Ra-deﬁcient
mice that rapidly develop arthritis-like symptoms. In this
context, stimulation of chondrocytes with extracellular
S100A8 activated the NF-κB pathway and the subsequent
release of cytokines and several MMPs,295 and this stimulatory
activity was subsequently attributed to signaling through
TLR4.296 It is also interesting to note that RAGE expression
increases in the joints of arthritic mice.297 Indeed, an Ager
gene polymorphism coding for the G82S mutation was shown
to increase the binding of S100A12 in vitro and promoted
S100A12-induced inﬂammation.297 This is even more interest-
ing because this Ager G82S polymorphism has a higher
prevalence in RA patients.297 Local intra-articular corticoster-
oid treatment of RA patients induced reduced concentrations
of serum and synovial S100A12, further linking calgranulins to
the arthritic joint inﬂammatory environment.293 Together,
these studies demonstrate the central role of S100A8/A9
and S100A12 in the establishment of the inﬂammatory micro-
environment present in the arthritic joints and the
metalloproteinase-dependent destruction of cartilage. It is also
worth noting that the synovial ﬂuid level of calgranulins found
in active arthritic joints is higher than the serum levels, further
supporting the idea of an intra-articular origin of calgranulins
(inﬁltrating macrophages and granulocytes or chondro-
cytes).247,294,298 However, the exact role of TLR4 or RAGE in
this context is not yet entirely clear.
In addition to calgranulins, both S100A4 and S100B
were found to activate the ERK1/2 and NF-κB proinﬂamma-
tory pathways through RAGE expressed at the surface of
chondrocytes, thereby triggering an increase in MMP13
expression that could potentially contribute to arthritic carti-
lage destruction.299,300
Notably, several S100 proteins have been linked to the
development of skin lesions in psoriasis. Indeed, S100A8/A9
levels were shown to be elevated in psoriatic skin lesions.301,302
Stimulation of normal keratinocytes with S100A8/A9 induced
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the secretion of proinﬂammatory cytokines and chemokines
that in turn promoted S100A8/A9 expression in an autocrine-
positive feedback loop,303 thus mimicking the proinﬂammatory
environment found in psoriatic lesions. Furthermore, S100A7
and S100A15 were shown to promote the chemoattraction of
monocytes, neutrophils and CD4+ T cells and trigger the
production of proinﬂammatory cytokines in the context of
psoriatic skin lesions.304–306 However, only S100A7 required
RAGE for its chemotactic activity,304 underlining potential
differences in the role of S100A7 and S100A15 in psoriasis.
S100 proteins and cancer
Like all of the alarmins described above, several S100 proteins
have been identiﬁed as central mediators for the development
of a multitude of cancers and have been shown to contribute to
tumor cell proliferation, metastasis, angiogenesis and immune
evasion.307–309 The role of S100 proteins in cancer is considered
to be type and stage speciﬁc, and each type of cancer seems to
exhibit a different S100 protein proﬁle.307 Several groups
recently reviewed the intricate role of S100 proteins in cancer
in great detail.307–309
CONCLUDING REMARKS
A large body of evidence suggests that several proteins hidden
inside cells have both intracellular roles and extracellular
functions that contribute to the rapid recruitment and response
of the immune system to infection and damage. During
chronic damage and metabolic perturbations, these proteins
are integral to complex proinﬂammatory events with shared
regulatory mechanisms that result in either tissue repair or
tissue damage and organ dysfunction. The pharmacological
targeting of such DAMPs could therefore be of beneﬁt.
However, alarmins have intricate local and systemic roles
which depend on their post-translational modiﬁcation status,
differential receptor engagement and the cell-type affected.
Thus, targeting alarmins remains challenging.
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